Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B-cell mediated autoimmune disease. Their lead product candidate, DSG3-CAART, is entering clinical development as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. Co-founder Dr. Aimee Payne, MD, PhD is a worldwide leader in characterizing B cell-mediated autoantibody repertoires in pemphigus vulgaris and other autoimmune diseases. We discuss with Dr. Payne on how she translated research out of her lab into a full-fledged company and how she is keen on mentoring female physician-scientists to improve representation of women in healthcare leadership.